companydata.dkcompanydata.dk

UNIKUM Therapeutics ApS: Financial statements 2023

CVR: 41192925

Source: annual report 2023, Danish Business Authority

01/01/2023 – 31/12/2023

UNIKUM Therapeutics ApS (CVR 41192925) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -7,465,410 and a net result of DKK -14,870,759 compared with DKK -7,648,614 the year before. Equity in the 2023 report amounted to DKK -16,283,891. The company had 9 employees in the financial year.

Gross Profit
DKK -7,465,410
Profit/Loss
DKK -14,870,759
Equity
DKK -16,283,891
Total Assets
DKK 3,996,302
Employees
9

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2023--7.5M-14.9M-16.3M9
2022--3.3M-7.6M-15.3M7
2021--2.7M-5.6M-7.6M5
2020--1.1M-2.1M-2.1M2

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2023

MEDIC ADVICE ApS registered as owner of UNIKUM Therapeutics ApSOct 4, 2023

As of October 4, 2023, MEDIC ADVICE ApS is registered as an owner of UNIKUM Therapeutics ApS with an ownership share of 5%.

RO Bak Holding ApS registered as owner of UNIKUM Therapeutics ApSOct 4, 2023

As of October 4, 2023, RO Bak Holding ApS is registered as an owner of UNIKUM Therapeutics ApS with an ownership share of 5%.

Rasmus Otkjær Bak steps down as adm. dir. of UNIKUM Therapeutics ApSSep 30, 2023

As of September 30, 2023, Rasmus Otkjær Bak has stepped down as adm. dir. of UNIKUM Therapeutics ApS.

Margo Rosemary Roberts joins the board of UNIKUM Therapeutics ApSAug 1, 2023

As of August 1, 2023, Margo Rosemary Roberts has joined the board of directors of UNIKUM Therapeutics ApS.

UNIKUM Therapeutics ApS: The 2022 annual report is outMay 11, 2023

UNIKUM Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK -3,315,358, and the net result was DKK -7,648,614.

Rasmus Otkjær Bak joins UNIKUM Therapeutics ApS as adm. dir.Apr 18, 2023

As of April 18, 2023, Rasmus Otkjær Bak is registered as adm. dir. of UNIKUM Therapeutics ApS.

Tommi Petteri Kainu joins UNIKUM Therapeutics ApS as directorApr 18, 2023

As of April 18, 2023, Tommi Petteri Kainu is registered as director of UNIKUM Therapeutics ApS.

Rasmus Otkjær Bak steps down as director of UNIKUM Therapeutics ApSApr 17, 2023

As of April 17, 2023, Rasmus Otkjær Bak has stepped down as director of UNIKUM Therapeutics ApS.

Johannes Heinrich Frühauf joins the board of UNIKUM Therapeutics ApSMar 2, 2023

As of March 2, 2023, Johannes Heinrich Frühauf has joined the board of directors of UNIKUM Therapeutics ApS.

Nebojsa Milovic joins the board of UNIKUM Therapeutics ApSMar 2, 2023

As of March 2, 2023, Nebojsa Milovic has joined the board of directors of UNIKUM Therapeutics ApS.

About UNIKUM Therapeutics ApS

UNIKUM Therapeutics ApS is a Danish company of the type Anpartsselskab based in Risskov, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Martin Roelsgaard Jakobsen. The board consists of Ulrik Bjerl Nielsen (chair), Martin Roelsgaard Jakobsen and Stefan Wildt. The company's owners include MEDIC ADVICE ApS, MR Jakobsen Holding ApS and BII Holdings A/S. The company has 2 employees (2025). In 2025, the company reported a gross profit of DKK -247,887 and a net result of DKK -859,076 compared with DKK -13,797,011 the year before. Equity in the 2025 report amounted to DKK -5,680,033.

Source: annual report 2025, Danish Business Authority

Other financial years